United States

PharmaVigilant releases I-Accountability to enhance traceability of drug inventory

Friday, December 7, 2012 02:33 AM

PharmaVigilant, a software developer based in Westborough, Mass., has released I-Accountability, a drug accountability system that efficiently tracks and controls drug inventory and randomization.

More... »

Geron discontinues GRN100, cuts 43 workers

Wednesday, December 5, 2012 11:08 AM

Geron, a Menlo Park, Calif.-based biopharmaceutical company developing first-in-class therapies for cancer, has discontinued development of GRN1005, its peptide-drug conjugate designed to treat cancers in the brain. Going forward, the company will focus on the development of imetelstat, its telomerase inhibitor, in hematologic myeloid malignancies and in patients with solid tumors that have short telomeres.

More... »

AAIPharma appoints Browne as director of analytical chemistry

Wednesday, December 5, 2012 11:02 AM

AAIPharma Services, a provider of pharmaceutical product development services, has appointed David Browne as the company's director of analytical chemistry for its Edison, N.J., laboratory.

More... »

Synthetic completes acquisition of C. difficile infectious disease program

Tuesday, December 4, 2012 08:00 AM

Synthetic Biologics, an Ann Arbor, Mich.-based developer of synthetic biologics and innovative medicines for serious infections and diseases, has closed the previously announced deal with Prev AbR and acquired a series of beta-lactamase compounds (P1A, P2A and P3A) and related assets targeting the prevention of Clostridium difficile (C. diff) infection.

More... »

Omeros appoints Mitro as vice president, sales and marketing

Tuesday, December 4, 2012 08:00 AM

Omeros, a Seattle, Wash.-based clinical-stage biopharmaceutical company focused on products targeting inflammation, coagulopathies and disorders of the central nervous system, has appointed Thomas A. Mitro as vice president of sales and marketing.

More... »

Volcano to acquire Crux Biomedical

Monday, December 3, 2012 11:21 AM

Volcano, a developer and manufacturer of precision guided therapy tools for treatment of coronary and peripheral vascular disease, has signed an agreement to acquire Crux Biomedical, a privately-held company that has developed a highly differentiated inferior vena cava (IVC) filter—the Crux VCF System—to treat pulmonary embolisms (PE's).

More... »

BioCryst, Presidio mutually terminate merger

Friday, November 30, 2012 01:50 PM

BioCryst Pharmaceuticals, a biopharmaceutical company focused on infectious and inflammatory diseases, and privately held Presidio Pharmaceuticals, a San Francisco-based clinical stage specialty pharmaceutical company focused on small molecule antiviral therapeutics, have agreed to the mutual termination of their Merger Agreement and the related Investor Financing Agreement entered into on October 17, 2012.

More... »

Boston Scientific enrolls first patient in coronary stent study featuring bioabsorbable polymer coating

Friday, November 30, 2012 12:13 PM

The first patient has been enrolled in Boston Scientific’s EVOLVE II clinical trial, designed to further assess the safety and effectiveness of the SYNERGY Stent System and support FDA and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.  

More... »

Ampio Pharmaceuticals names Disbrow as COO

Friday, November 30, 2012 11:45 AM

Ampio Pharmaceuticals, a Greenwood Village, Colo.-based biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, has appointed Josh Disbrow as chief operating officer.

More... »

Common canine virus may lead to new vaccines for deadly human diseases

Friday, November 30, 2012 11:21 AM

Researchers at the University of Georgia have discovered that a virus commonly found in dogs may serve as the foundation for the next great breakthrough in human vaccine development.

More... »